DRUG Company Profile and Key Details

Bright Minds Biosciences Inc. has 9.81 million shares outstanding. The public float is 6.21 million shares, elevated short interest at 11.78% of float. This equals 890.85 thousand shares. The short ratio is 3.39 days. Institutional investors hold 105.69% of the float. Insiders own 12.0%. Over the past six months, insider transactions show net selling. They sold 109.33 thousand shares across 1 transactions.

Short-term trend indicators are mixed aligned (SMA20 6.01%, SMA50 2.19%, SMA200 56.62%). The stock’s 14-day RSI is 53.78 (neutral), while the ATR of 6.0 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -30.91% below its high and over 268.93% above its low. Average 10-day trading volume of 89.56 thousand shares is below the 3-month average of 187.90 thousand, indicating normal recent market interest.

Bright Minds Biosciences Inc. (NASDAQ:DRUG) closed at $59.62 USD, losing -$1.36 (-2.23%) from the previous close of $60.98. The stock is currently mid-range between its 52-week high and low $48.90 and $123.75. With a market capitalization of about $583.51 million, Bright Minds Biosciences Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.09). Key stats such as the average daily volume over the past year has been around 190.17 thousand shares, volume is running light vs its 52-week average. Headquartered in New York, NY, Bright Minds Biosciences Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ian McDonald, the company employs approximately 26 people and listed since March 22, 2021. Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.

Our AI price prediction model suggests that Bright Minds Biosciences Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -18.73%, with price expected at $49.56 by October 02, 2026, within a range of $47.32 to $51.85 3-Month Outlook: Projected rise of 34.6%, reaching $82.08 by December 17, 2026, with a range of $80.63 to $83.69. 1-Year Outlook: Projected gain of 62.25%, with price at $98.94 by September 17, 2027, within a range of $93.34 to $103.25.